Safety of Interferon Products: a Retrospective Analysis of Adverse Reactions Spontaneously Reported in the Republic of Crimea
Alexander V. Matveev,
Elena A. Egorova,
Ksenia N. Koryanova,
Elvira Y. Bekirova,
Nazife L. Suleymanova https://doi.org/10.36107/hfb.2021.i3.s117
Abstract
The modern pharmaceutical market is represented by a large number of natural and synthetic (recombinant) interferon drugs, available in different dosage forms for both local and systemic action, but the data on the safety of this group of drugs is rather limited. This requires additional study of the features and severity of adverse reactions (AR) associated with the use of this pharmaceutical group in the treatment of various nosologies. The aim of the study was to study the main manifestations and the incidence of AR when using drugs of the interferon group in patients living in the Republic of Crimea. The objects of the study were the cards-notifications about AR registered in the regional database (Republic of Crimea) of data of AR ARCADE (Adverse Reactions in Crimea, Autonomic Database) for the period 01.01.2010-31.12.2018. The analysis of spontaneous messages was carried out according to the following indicators: correspondence of the dose of the drug that caused the AR, the patient’s age, indications for the use of the suspected drug, the distribution of the presented AR cases by the route of drug administration, clinical manifestations of AR, patients’ allergological history, drug correction and measures, directed to stop AR and the number of simultaneously prescribed drugs. During the analyzed period, in the ARCADe database 57 cases of AR of the interferons were registered. Interferon alfa-2b drugs were the leaders in the frequency of AR development. The total number of registered AR cases for them was 42 cases (73.7% of the total number of cases). The most frequent clinical manifestations of AR were allergic reactions of the immediate type (48 cases, 84.2%), among which local allergic reactions in the form of urticaria, hyperemia, papular rash predominated (45 cases, 79%). Immediate life-threatening allergic reactions after administration of interferon alfa- 2b were observed in 3 cases: 2 cases (3,5%) of angioedema (Quincke’s edema) and 1 case of anaphylactic shock. The results obtained indicate a sufficient risk of developing life- threatening conditions against the background of the use of drugs of the interferon group, which requires healthcare professionals to carefully study the patient’s allergic history, as well as control his well-being at the entire stage of treatment.
About the Authors
Alexander V. Matveev
Institute “Medical Academy named after S. I. Georgievsky FGAOU HE “KFU im. IN AND. Vernadsky”
Russian Federation
Russian Federation
Elena A. Egorova
Institute “Medical Academy named after S. I. Georgievsky FGAOU HE “KFU im. IN AND. Vernadsky”
Russian Federation
Russian Federation
Ksenia N. Koryanova
Pyatigorsk Medical and Pharmaceutical Institute - branch of the Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Elvira Y. Bekirova
Institute “Medical Academy named after S. I. Georgievsky FGAOU HE “KFU im. IN AND. Vernadsky”
Russian Federation
Russian Federation
Nazife L. Suleymanova
Institute “Medical Academy named after S. I. Georgievsky FGAOU HE “KFU im. IN AND. Vernadsky”
Russian Federation
Russian Federation
References
1. Баранаева Е. А. (2016). Острые респираторные вирусные инфекции у детей: клинические особенности, современные возможности профилактики и лечения. Международные обзоры: клиническая практика и здоровье, 2, 6–15.
2. Василевский И. В. (2015). Клинико-фармакологическая стратегия использования в педиатрической практике индукторов интерферона. Педиатрия. Восточная Европа, 1, 88–100.
3. Вахитов, Х. М., Пикуза, О. И., Вахитова, Л. Ф., Закирова, А. М., Ризванова, Ф. Ф. (2019). Индукторы интерферона в профилактике и лечении респираторных инфекций у детей. Российский вестник перинатологии и педиатрии, 64(3), 103–108. http://dx.doi.org/10.21508/1027– 4065–2019–64–3–103–108
4. Денисов, Л. А., Шолохов, И. В. (2017). Открытие интерферона и его клиническое применение. Инфекционные болезни: Новости. Мнения. Обучение, 1(18), 23-31. http://dx.doi.org/10.24411/2305-3496-2017-00019
5. Дьякова С. Э. (2016). Оптимизация терапии (частых) острых респираторных инфекций у детей: от теории к практике. Практика педиатра, 11/12, 10–13.
6. Наровлянский, А. Н., Ершов Ф. И., Гинцбург А. Л. (2013). Интерфероны: перспективы направления исследований. Иммунология, 3, 168—172.
7. Суровенко, Т. Н., Присеко, Л. Г. (2018). Применение препаратов интерферона и его индукторов в амбулаторной педиатрической практике. Тихоокеанский медицинский журнал, 4, 79-83. http://dx.doi.org/10.17238/PmJ1609-1175.2018.4.79–83
8. Юнусов, А. Г., Зарифова, П. Г., Негматуллаева, С. М., Ниязова, Н. Н., Холова, Т. Н. (2019) Применение интерферонов в комплексной терапии дыхательных расстройств у недоношенных новорожденных. Лечащий врач, 6, 27-29. http://dx.doi.org/10.26295/OS.2019.27.75.006
9. Davoodi, L., Masoum, B., Moosazadeh, M., Jafarpour, H., Haghshenas, M.R., & Mousavi, T. (2018). Psychiatric side effects of pegylated interferon α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta analysis. Experimental and Therapeutic Medicine, 16, 971-978. https://doi.org/10.3892/etm.2018.6255.
10. Dusheiko G. (1997). Side effects of alpha interferon in chronic hepatitis C. Hepatology, 3, Suppl 1, 112S-121S. http://dx.doi.org/10.1002/hep.510260720
11. Gallina, K., Brodell, R. T., Naffah, F., & Nedorost S. (2003). Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C. Journal of Drugs in Dermatology, 2, 63–7.
12. Isaacs, A., Lindenmann, J., & Valentine, R. C. (1957). Virus interference. II. Some properties of interferon. Proceedings of the Royal Society of London.Biological Sciences, 147(927), 268–273.
13. Kerl, K., Negro, F., & Lubbe J. (2003). Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. BBritish Journal of Dermatology, 149, 656
14. Mistry, N., Shapero, J., Crawford, R. I. (2009). A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Canadian Journal of Gastroenterology and Hepatology, 10, 677-83. http://dx.doi.org/10.1155/2009/651952
15. Sleijfer, S., Bannink, M., Van Gool, A. . et al. (2005). Side Effects of Interferon-α Therapy. Pharmacy World & Science, 27, 423. https://doi.org/10.1007/s11096-005-1319-7.
16. Vassilopoulou-Sellin R. (1994). Endocrine effects of cytokines. Oncology, 8, 43-46.
17. Valentine, A. D., Meyers C. A., Kling, M. A., Richelson, E., & Hauser P. (1998). Mood and cognitive side effects of interferon-α therapy. Seminars in Oncology, 25 (1 Suppl 1), 39-47.
18. Vazquez-Lopez, F., Manjon-Haces, J. A., Perez-Alvarez, R., & Perez-Oliva N. (2004). Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: The value of an interdisciplinary assessment. British Journal of Dermatology, 150, 1046–7.
Review
For citations:
Matveev A.V., Egorova E.A., Koryanova K.N., Bekirova E.Y., Suleymanova N.L. Safety of Interferon Products: a Retrospective Analysis of Adverse Reactions Spontaneously Reported in the Republic of Crimea. Health, Food & Biotechnology. 2021;3(3). (In Russ.) https://doi.org/10.36107/hfb.2021.i3.s117
Views:
594
Email this article 